drugset / Trial / NCT05593588

Senolytics Treatment of Interstitial Lung Disease in Common Variable Immunodeficiency

NCT05593588

Phase 2 Active not recruiting 20 enrolled Avni Joshi
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if the supplement, Fisetin, can be used as a treatment option for common variable immunodeficiency (CVID) by comparing its efficacy to placebo.

Timeline

Start
2023-04-12
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Fisetin Small molecule 20 mg/kg Oral